In order to reduce lung PARP‐1 activity, we used 2‐dimethylaminomethyl‐9‐hydroxy‐thieno[2,3‐c]isoquinolin‐5(4H)‐one) (HYDAMTIQ) a potent PARP‐1/2 inhibitor (IC50 2–20 nM), previously characterized in models of brain ischaemia–reperfusion damage and of ovalbumin‐induced asthma in guinea pigs 31, 32, 33. This evidence concerns the gene PARP1 and asthma.